MAKEI V (Germ cell tumors)
Open, not recruiting
Who can enter
Children with a newly diagnosed extracranial germ cell tumor
0-18 years
Goal
Goal
The goal of this study is to improve the treatment of children with a newly diagnoses extracranial germ cell tumor.
Background
Background
Some children with germ cell tumors are treated with courses of chemotherapy. One of the most important and widely used drugs in the treatment of germ cell tumors is cisplatin. This drug has been shown to be effective, but is also known to cause side effects and late effects.
Carboplatin has a similar effect and causes fewer side effects in most patients. In this study we want to investigate whether carboplatin is as effective as cisplatin, and whether carboplatin indeed causes fewer side effects.
This study is closed for participation.
Last reviewed
Last reviewed
January 8, 2026
Study details
- Study details
Official title
Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and CisplatinCancer type
Extracranial germ cell tumorPhase
3Maximum number of patients
360, of whom 25 are expected to participate in the NetherlandsStart date
August 29, 2023Status
Closed for participationLocal principal investigator
Dr. A.M.C. Mavinkurve-GroothuisSponsor
University of Bonn, GermanyApproval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.Trial registry number
EU Clinical Trials Register: 2016-001784-36
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.